Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H30N3O5.Na |
| Molecular Weight | 427.4698 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].NCCCC[C@H](N[C@H](CCC1=CC=CC=C1)C([O-])=O)C(=O)N2CCC[C@H]2C(O)=O
InChI
InChIKey=MIRTZIYIUNFNIM-RXQQAGQTSA-M
InChI=1S/C21H31N3O5.Na/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);/q;+1/p-1/t16-,17+,18-;/m0./s1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C21H30N3O5 |
| Molecular Weight | 404.48 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19946889
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19946889
(R)-Lisinopril Sodium Salt is the R,S,S-Isomer of Lisinopril. Lisinopril is a potent inhibitor of angiotensin-converting enzyme (ACE). Lisinopril prevents the conversion of angiotensin I to angiotensin II, which acts as a potent vasoconstrictor and also signals the release of aldosterone, which modulates sodium absorption. ACE inhibition has the net result of vasodilation and increased sodium and water excretion. Lisinopril, (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]
hexanoyl]pyrrole-2-carboxylic acid is an angiotensin-converting
enzyme (ACE) inhibitor, used for the treatment of hypertension,
heartfailure andacutemyocardial infarction. The
RSS isomer of lisinopril ((2S)-1-[(2S)-6-amino-2-[[(1R)-1-carboxy-
3-phenylpropyl]amino]hexanoyl]pyrrole-2-carboxylic acid) is an
impurity (impurity E) resulting from the synthesis of lisinopril. The impurity profile of a drug substance is critical to its safety
assessment and is important for monitoring the manufacturing
process.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 20:18:24 GMT 2025
by
admin
on
Wed Apr 02 20:18:24 GMT 2025
|
| Record UNII |
FGL9YNW4JT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
131667857
Created by
admin on Wed Apr 02 20:18:24 GMT 2025 , Edited by admin on Wed Apr 02 20:18:24 GMT 2025
|
PRIMARY | |||
|
FGL9YNW4JT
Created by
admin on Wed Apr 02 20:18:24 GMT 2025 , Edited by admin on Wed Apr 02 20:18:24 GMT 2025
|
PRIMARY | |||
|
1356019-70-9
Created by
admin on Wed Apr 02 20:18:24 GMT 2025 , Edited by admin on Wed Apr 02 20:18:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|